Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:684 |
Name | hepatocellular carcinoma |
Definition | A liver carcinoma that has_material_basis_in undifferentiated hepatocytes and located_in the liver. |
Source | DiseaseOntology.org |
Alt Ids | DOID:5005 |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer liver cancer liver carcinoma hepatocellular carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | FH535 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Fluorouracil + Interferon alpha-2b | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Linifanib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Sorafenib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Torin 2 | hepatocellular carcinoma | not applicable | detail... |
CTNNB1 mutant | PMED-1 | hepatocellular carcinoma | sensitive | detail... |
Unknown unknown | LCL161 + Paclitaxel | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Fingolimod + Sorafenib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | PI-88 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Lenvatinib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | NanoHHI | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | OPB-31121 | hepatocellular carcinoma | no benefit | detail... |
Unknown unknown | YW3-56 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Ascrinvacumab | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | NSC156529 | hepatocellular carcinoma | not applicable | detail... |
BCORL1 over exp | N/A | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | 17-Demethoxy-reblastatin | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Refametinib + Sorafenib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Resminostat + Sorafenib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Domatinostat | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Lenalidomide + Sorafenib | hepatocellular carcinoma | no benefit | detail... |
Unknown unknown | Codrituzumab | hepatocellular carcinoma | no benefit | detail... |
Unknown unknown | Brivanib | hepatocellular carcinoma | no benefit | detail... |
Unknown unknown | Ramucirumab | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Selumetinib + Sorafenib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Erlotinib + Sorafenib | hepatocellular carcinoma | no benefit | detail... |
FGFR1 pos FGFR2 pos | AZD4547 | hepatocellular carcinoma | sensitive | detail... |
FGFR1 pos FGFR2 pos | PHA-665752 | hepatocellular carcinoma | no benefit | detail... |
Unknown unknown | SF1126 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | SF1126 + Sorafenib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Metformin + Sorafenib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Cabozantinib + CT-707 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | CT-707 + PHA-665752 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Regorafenib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Droxinostat | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Chiauranib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | PEGPH20 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Riluzole | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Foretinib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | RU-A1 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Fluorouracil + RU-A1 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Nivolumab | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | CEBPA-51 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | SGI-1027 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | KU-0063794 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Camrelizumab | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | GNS561 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Bevacizumab + MINT1526A | hepatocellular carcinoma | not applicable | detail... |
NRAS mutant | Refametinib + Sorafenib | hepatocellular carcinoma | sensitive | detail... |
Unknown unknown | Pembrolizumab | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Cabozantinib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Camrelizumab + Rivoceranib | hepatocellular carcinoma | not applicable | detail... |
PIK3CA mutant | Sorafenib | hepatocellular carcinoma | decreased response | detail... |
CTNNB1 act mut | unspecified PD-1 antibody | hepatocellular carcinoma | decreased response | detail... |
CTNNB1 act mut | unspecified PD-L1 antibody | hepatocellular carcinoma | decreased response | detail... |
CTNNB1 act mut | unspecified CTLA4 antibody | hepatocellular carcinoma | decreased response | detail... |
CTNNB1 act mut | unspecified CTLA4 antibody + unspecified PD-1 antibody | hepatocellular carcinoma | decreased response | detail... |
Unknown unknown | Orlistat | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Orlistat + Paclitaxel | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Dalantercept + Sorafenib | hepatocellular carcinoma | no benefit | detail... |
Unknown unknown | Mogamulizumab + Nivolumab | hepatocellular carcinoma | not applicable | detail... |
ATRX del | Adavosertib | hepatocellular carcinoma | sensitive | detail... |
Unknown unknown | Ipilimumab + Nivolumab | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Novaferon | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | DRP-104 + unspecified PD-L1 antibody | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | DRP-104 | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Atezolizumab + Bevacizumab | hepatocellular carcinoma | not applicable | detail... |
FLT3 over exp | Sorafenib | hepatocellular carcinoma | sensitive | detail... |
Unknown unknown | Mipsagargin | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Intuvax | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Intuvax + Sorafenib | hepatocellular carcinoma | not applicable | detail... |
Unknown unknown | Avelumab | hepatocellular carcinoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00986661 | Phase I | PV-10 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | Recruiting | USA | 0 |
NCT01015833 | Phase III | Doxorubicin Sorafenib | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | Active, not recruiting | USA | CAN | 1 |
NCT01075113 | Phase I | Sorafenib + Vorinostat | Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer | Completed | USA | 0 |
NCT01141478 | Phase I | Sorafenib | Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria | Unknown status | USA | 0 |
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Suspended | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | 3 |
NCT01246986 | Phase II | Galunisertib + Sorafenib Galunisertib | A Study of LY2157299 in Participants With Hepatocellular Carcinoma | Completed | USA | 6 |
NCT01306058 | Phase Ib/II | Carotuximab + Sorafenib | Sorafenib and TRC105 in Hepatocellular Cancer | Completed | USA | 0 |
NCT01356628 | Phase II | Palbociclib | A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | Active, not recruiting | USA | 0 |
NCT01421524 | Phase I | CC-122 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | Active, not recruiting | USA | 4 |
NCT01556490 | Phase III | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer | Active, not recruiting | USA | CAN | 9 | |
NCT01567930 | Phase II | Temsirolimus | Temsirolimus as Second-line Therapy in HCC | Unknown status | USA | 0 |
NCT01624285 | Phase II | Sorafenib | Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | Active, not recruiting | USA | 0 |
NCT01628640 | Phase I | VSV-IFN-beta | Viral Therapy in Treating Patient With Liver Cancer | Active, not recruiting | USA | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Active, not recruiting | USA | 0 |
NCT01655693 | Phase III | Doxorubicin | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive) | Completed | USA | 10 |
NCT01658878 | Phase I | Nivolumab | Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma) | Active, not recruiting | USA | CAN | 11 |
NCT01666756 | Phase I | Sorafenib + YIV-906 | Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | Completed | USA | 0 |
NCT01687673 | Phase II | Sorafenib + Temsirolimus | Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | Completed | USA | 0 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | 5 |
NCT01730937 | Phase III | Sorafenib | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | Recruiting | USA | CAN | 3 |
NCT01754987 | Phase Ib/II | Sorafenib | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | Completed | USA | 0 |
NCT01755767 | Phase III | Tivantinib | Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy | Completed | USA | CAN | 14 |
NCT01761266 | Phase III | Lenvatinib Sorafenib | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | CAN | 19 |
NCT01774344 | Phase III | Regorafenib | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE) | Completed | USA | 20 |
NCT01775501 | Phase II | Sorafenib Fluorouracil Oxaliplatin Leucovorin | Sorafenib + mFOLFOX for Hepatocellular Carcinoma | Completed | USA | 0 |
NCT01801163 | Phase I | Sorafenib | A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) | Withdrawn | USA | 0 |
NCT01835223 | Phase Ib/II | Tivozanib | Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01840592 | Phase II | Doxorubicin + Sorafenib | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | Active, not recruiting | USA | 0 |
NCT01849588 | FDA approved | Sorafenib | Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C | Terminated | USA | 0 |
NCT01853618 | Phase I | Tremelimumab | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | Completed | USA | 0 |
NCT01887717 | Phase III | Sorafenib | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein | Terminated | USA | 5 |
NCT01900002 | Phase II | Sorafenib | Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC) | Completed | USA | 0 |
NCT01908426 | Phase III | Cabozantinib | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Unknown status | USA | CAN | 17 |
NCT01915602 | Phase II | Refametinib + Sorafenib | Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) | Completed | USA | 20 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | 2 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Recruiting | USA | CAN | 13 |
NCT01999738 | Phase I | EC1456 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02024087 | Phase Ib/II | Dalantercept + Sorafenib | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | Completed | USA | 0 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02069145 | Phase I | Ipafricept + Sorafenib | Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer | Completed | USA | 0 |
NCT02072486 | Phase I | Sorafenib | Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02082210 | Phase Ib/II | Emibetuzumab + Ramucirumab | A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | Completed | USA | 0 |
NCT02101593 | Phase I | ADI-PEG 20 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | Completed | USA | 0 |
NCT02128958 | Phase II | CF102 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Active, not recruiting | USA | 4 |
NCT02143401 | Phase I | Navitoclax + Sorafenib | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | Active, not recruiting | USA | 0 |
NCT02151864 | Phase I | Sonidegib | LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis | Completed | USA | 0 |
NCT02174549 | Phase I | Tirapazamine | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | Active, not recruiting | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02227914 | Phase Ib/II | Oprozomib Sorafenib | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | Withdrawn | USA | 0 |
NCT02232633 | Phase II | BBI503 | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | Completed | CAN | 0 |
NCT02279719 | Phase Ib/II | Sorafenib BBI503 + Sorafenib Napabucasin + Sorafenib | A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma | Completed | USA | 0 |
NCT02288507 | Phase I | Sorafenib | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | Withdrawn | USA | 0 |
NCT02292173 | Phase I | Sorafenib + Trametinib | Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | Active, not recruiting | USA | 0 |
NCT02314052 | Phase Ib/II | DCR-MYC | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma | Terminated | USA | 2 |
NCT02315066 | Phase I | PF-04518600 PF-04518600 + Utomilumab | Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 | Completed | USA | 3 |
NCT02323906 | Phase Ib/II | CC-122 + Sorafenib | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | Terminated | USA | 0 |
NCT02406508 | Phase II | Melphalan Sorafenib | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC | Withdrawn | USA | 0 |
NCT02423343 | Phase Ib/II | Galunisertib Nivolumab | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma | Completed | USA | 1 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02435433 | Phase III | Ramucirumab | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2) | Recruiting | USA | CAN | 18 |
NCT02460991 | Phase I | Sorafenib Doxorubicin | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma | Terminated | USA | 0 |
NCT02508467 | Phase I | Fisogatinib | A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma | Active, not recruiting | USA | 11 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Recruiting | USA | 8 |
NCT02519348 | Phase II | Tremelimumab Durvalumab | A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | 8 |
NCT02524119 | Phase II | Ribociclib | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001) | Terminated | USA | 0 |
NCT02528643 | Phase II | Enzalutamide | A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma | Active, not recruiting | USA | CAN | 7 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | 1 |
NCT02560779 | Phase Ib/II | Carotuximab + Sorafenib | Trial of TRC105 and Sorafenib in Patients With HCC | Completed | USA | 0 |
NCT02562755 | Phase III | JX-594 Sorafenib | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone | Completed | USA | CAN | 14 |
NCT02564614 | Phase I | EZN-2968 | A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC) | Completed | USA | 0 |
NCT02572687 | Phase I | Durvalumab + Ramucirumab | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | Completed | USA | 7 |
NCT02575339 | Phase Ib/II | Sorafenib Sapanisertib | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT02576509 | Phase III | Nivolumab Sorafenib | A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma | Active, not recruiting | USA | CAN | 20 |
NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Recruiting | USA | 0 |
NCT02597036 | Phase I | LY3127804 Ramucirumab | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | Completed | USA | 3 |
NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
NCT02642913 | Phase Ib/II | Enzalutamide Sorafenib | Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients | Active, not recruiting | USA | 0 |
NCT02658019 | Phase II | Pembrolizumab | Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | Completed | USA | 0 |
NCT02675946 | Phase I | CGX1321 | Study of CGX1321 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT02702401 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Active, not recruiting | 0 | |
NCT02702414 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Active, not recruiting | 0 | |
NCT02715531 | Phase I | Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | Active, not recruiting | USA | 6 |
NCT02795429 | Phase Ib/II | Spartalizumab Capmatinib + Spartalizumab | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | Active, not recruiting | CAN | 7 |
NCT02821754 | Phase Ib/II | Durvalumab + Tremelimumab | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | Recruiting | USA | 0 |
NCT02834780 | Phase I | H3B-6527 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma | Active, not recruiting | USA | CAN | 9 |
NCT02837029 | Phase I | Nivolumab | Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer | Active, not recruiting | USA | 0 |
NCT02842125 | Phase I | Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab | Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | Terminated | USA | 0 |
NCT02859324 | Phase Ib/II | CC-122 + Nivolumab | A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | Completed | USA | 3 |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT02905188 | Phase I | GLYCAR T cells Cyclophosphamide + Fludarabine | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (GLYCAR) | Recruiting | USA | 0 |
NCT02906397 | Phase I | Galunisertib | A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC) | Active, not recruiting | USA | 0 |
NCT02939807 | Phase II | ABC294640 | A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma | Withdrawn | USA | 0 |
NCT02940496 | Phase Ib/II | Pembrolizumab | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Active, not recruiting | USA | CAN | 7 |
NCT02960594 | Phase I | INO-1400 + INO-9012 INO-1400 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Completed | USA | 0 |
NCT02988440 | Phase I | Sorafenib + Spartalizumab | Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | Completed | USA | CAN | 6 |
NCT02989870 | Phase I | Bavituximab + Sorafenib | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | Withdrawn | USA | 0 |
NCT03006926 | Phase I | Lenvatinib + Pembrolizumab | A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma | Active, not recruiting | USA | 6 |
NCT03037437 | Phase II | Hydroxychloroquine + Sorafenib | Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | Recruiting | USA | 0 |
NCT03059147 | Phase I | SF1126 | A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Recruiting | USA | 0 |
NCT03099564 | Phase I | Pembrolizumab | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | Recruiting | USA | 0 |
NCT03132792 | Phase I | AFPc332T | AFPc332T in Advanced HCC | Recruiting | USA | 3 |
NCT03138889 | Phase I | NKTR-214 + Pembrolizumab | A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (PROPEL) | Recruiting | USA | 5 |
NCT03143270 | Phase I | Nivolumab | A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer | Recruiting | USA | 0 |
NCT03144661 | Phase I | INCB062079 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | Terminated | USA | 1 |
NCT03145558 | Phase II | Doxorubicin Tirapazamine | TATE Versus TACE in Intermediate Stage HCC (TATE) | Active, not recruiting | USA | 0 |
NCT03203304 | Phase I | Nivolumab Ipilimumab + Nivolumab | Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT03211416 | Phase Ib/II | Pembrolizumab + Sorafenib | Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | Recruiting | USA | 0 |
NCT03222076 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) | Active, not recruiting | USA | 0 |
NCT03253289 | Phase I | Meclizine | Meclizine for Hepatocellular Carcinoma (OPTIM) | Suspended | USA | 0 |
NCT03257761 | Phase I | Durvalumab + Guadecitabine | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | Recruiting | USA | 0 |
NCT03259867 | Phase II | Nivolumab Pembrolizumab | Combination of TATE and PD-1 Inhibitor in Liver Cancer | Recruiting | USA | 0 |
NCT03298451 | Phase III | Sorafenib Durvalumab + Tremelimumab Durvalumab | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | Recruiting | USA | CAN | 15 |
NCT03299946 | Phase I | Cabozantinib + Nivolumab | Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | Active, not recruiting | USA | 0 |
NCT03316222 | Phase Ib/II | GNS561 | Study of GNS561 in Patients With Liver Cancer | Recruiting | USA | 2 |
NCT03316872 | Phase II | Pembrolizumab | Study of Pembrolizumab and Radiotherapy in Liver Cancer | Recruiting | CAN | 0 |
NCT03318562 | Phase II | Tomivosertib | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Terminated | USA | 0 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT03347292 | Phase I | Pembrolizumab + Regorafenib | Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | Active, not recruiting | USA | 1 |
NCT03382886 | Phase I | Bevacizumab + Nivolumab | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma (NUANCE) | Terminated | USA | 0 |
NCT03383458 | Phase III | Nivolumab | A Phase 3 Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | Active, not recruiting | USA | CAN | 24 |
NCT03412773 | Phase III | Tislelizumab Sorafenib | Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC | Active, not recruiting | USA | 10 |
NCT03416335 | Phase Ib/II | DSP-0509 DSP-0509 + Pembrolizumab | A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Recruiting | USA | 0 |
NCT03419897 | Phase II | Tislelizumab | Study of BGB-A317 in Patients With Previously Treated Unresectable HCC | Active, not recruiting | 8 | |
NCT03433703 | Phase II | Lenvatinib | Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) | Terminated | USA | 0 |
NCT03434379 | Phase III | Atezolizumab + Bevacizumab Sorafenib | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] | Recruiting | USA | CAN | 15 |
NCT03439891 | Phase II | Nivolumab + Sorafenib | Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | Active, not recruiting | USA | 0 |
NCT03441100 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin IMA202 | TCR-engineered T Cells in NSCLC and HCC Patients | Recruiting | USA | 1 |
NCT03482102 | Phase II | Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | Recruiting | USA | 0 |
NCT03511222 | Phase I | Pembrolizumab + Vorolanib Nivolumab + Vorolanib | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Recruiting | USA | 0 |
NCT03519997 | Phase II | Bavituximab + Pembrolizumab | A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT03533582 | Phase II | Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Carboplatin + Cisplatin + Doxorubicin + Etoposide Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine Sulfate Cisplatin Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | Recruiting | USA | CAN | 4 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03539822 | Phase I | Cabozantinib + Durvalumab | Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) | Recruiting | USA | 0 |
NCT03563170 | Phase Ib/II | Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Sorafenib Sorafenib | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | Withdrawn | USA | 0 |
NCT03582618 | Phase II | CVM-1118 + Sorafenib | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | Recruiting | USA | 1 |
NCT03637764 | Phase Ib/II | Atezolizumab + Isatuximab Isatuximab | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | Active, not recruiting | USA | CAN | 8 |
NCT03638141 | Phase II | Durvalumab + Tremelimumab | CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab | Recruiting | USA | 0 |
NCT03647163 | Phase I | Pembrolizumab + VSV-hIFNbeta-NIS | Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC | Recruiting | USA | 0 |
NCT03655002 | Phase I | Cyclophosphamide + IRX-2 + Nivolumab | IRX-2, Cyclophosphamide, and Nivolumab in Treating Participants With Recurrent or Metastatic and Refractory Liver Cancer | Recruiting | USA | 0 |
NCT03656718 | Phase Ib/II | Nivolumab + rHuPH20 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | Recruiting | USA | 10 |
NCT03665129 | Phase I | Durvalumab + IPH5401 | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) | Active, not recruiting | USA | 1 |
NCT03680508 | Phase II | Dostarlimab + TSR-022 | TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer | Recruiting | USA | 0 |
NCT03684811 | Phase Ib/II | Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib | A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Active, not recruiting | USA | 5 |
NCT03695250 | Phase Ib/II | BMS-986205 + Nivolumab | BMS-986205 and Nivolumab as First Line Therapy in Treating Patients With Liver Cancer | Recruiting | USA | 0 |
NCT03713593 | Phase III | Lenvatinib Lenvatinib + Pembrolizumab | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) | Active, not recruiting | USA | CAN | 19 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Recruiting | USA | 5 |
NCT03735628 | Phase Ib/II | Copanlisib + Nivolumab | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT03752398 | Phase I | XmAb23104 | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Recruiting | USA | 0 |
NCT03755791 | Phase III | Cabozantinib Sorafenib Atezolizumab + Cabozantinib | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312) | Recruiting | USA | CAN | 32 |
NCT03778957 | Phase III | Durvalumab Bevacizumab + Durvalumab | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) | Recruiting | USA | CAN | 16 |
NCT03781960 | Phase II | Abemaciclib + Nivolumab | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT03785210 | Phase II | Nivolumab + Tadalafil + Vancomycin | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | Recruiting | USA | 0 |
NCT03812562 | Phase I | Nivolumab | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | Active, not recruiting | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | 0 |
NCT03821935 | Phase I | ABBV-151 ABBV-151 + ABBV-181 | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 9 |
NCT03829501 | Phase Ib/II | Atezolizumab + KY1044 KY1044 | Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer | Recruiting | USA | 3 |
NCT03836352 | Phase II | DPX-Survivac + Pembrolizumab Cyclophosphamide + DPX-Survivac + Pembrolizumab | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | Recruiting | USA | CAN | 0 |
NCT03847428 | Phase III | Durvalumab Bevacizumab + Durvalumab | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2) | Recruiting | USA | CAN | 20 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Recruiting | USA | 0 |
NCT03867084 | Phase III | Pembrolizumab | Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) | Recruiting | USA | CAN | 28 |
NCT03897543 | Phase Ib/II | ABX196 + Nivolumab | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT03908840 | Phase I | TBI-302 | Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | Not yet recruiting | USA | 0 |
NCT03916627 | Phase II | Cemiplimab | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC | Recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Active, not recruiting | USA | 4 |
NCT03937830 | Phase II | Bevacizumab + Doxorubicin + Durvalumab | Combined Treatment of Durvalumab, Bevacizumab, and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT03964233 | Phase I | BI 754091 + BI 754111 + BI 907828 BI 754091 + BI 907828 BI 907828 | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) | Recruiting | USA | 1 |
NCT03970616 | Phase Ib/II | Durvalumab + Tivozanib | A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT03993873 | Phase I | TPX-0022 | Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET | Recruiting | USA | 3 |
NCT03998033 | Phase Ib/II | ET140202 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Recruiting | USA | 0 |
NCT04039607 | Phase III | Lenvatinib Sorafenib Ipilimumab + Nivolumab | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) | Recruiting | USA | CAN | 24 |
NCT04050462 | Phase II | BMS-986253 + Nivolumab Nivolumab Cabiralizumab + Nivolumab | A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients | Recruiting | USA | 0 |
NCT04095273 | Phase I | BAY1895344 + Pembrolizumab | Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | Recruiting | USA | 4 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04102098 | Phase III | Atezolizumab + Bevacizumab | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050) | Recruiting | USA | CAN | 23 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Recruiting | USA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04123379 | Phase II | BMS-813160 + Nivolumab Nivolumab BMS-986253 + Nivolumab | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | Recruiting | USA | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Active, not recruiting | USA | 0 |
NCT04134559 | Phase II | Pembrolizumab | Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | 0 |
NCT04158700 | Phase Ib/II | LY3200882 + Pembrolizumab | A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer | Withdrawn | USA | 2 |
NCT04175912 | Phase II | Carboplatin + MLN4924 + Paclitaxel MLN4924 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | Recruiting | USA | 0 |
NCT04204850 | Phase II | Cabozantinib | Cabozantinib to Treat of Recurrent Liver Cancer Post Transplant (CaboTx) | Recruiting | CAN | 0 |
NCT04246177 | Phase III | Lenvatinib + Pembrolizumab | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) | Recruiting | USA | 22 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04291105 | Phase II | Cemiplimab + VSV-hIFNbeta-NIS | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Recruiting | USA | 0 |
NCT04311710 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) | Recruiting | USA | 8 |
NCT04327700 | Phase II | Regorafenib | Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | Recruiting | USA | 0 |
NCT04340193 | Phase III | Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W) | Recruiting | USA | CAN | 20 |
NCT04374877 | Phase I | SRF388 | Study of SRF388 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04423029 | Phase Ib/II | DF6002 + Pembrolizumab DF6002 | Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications | Recruiting | USA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04430452 | Phase II | Durvalumab Durvalumab + Tremelimumab | Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition | Not yet recruiting | USA | 0 |
NCT04442581 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Recruiting | USA | 0 |
NCT04472767 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | Recruiting | USA | 0 |
NCT04476329 | Phase II | Regorafenib | Optimization for Regorafenib in HCC (ReDos HCC) | Recruiting | USA | 0 |
NCT04497038 | Phase Ib/II | Cabozantinib | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | Recruiting | USA | 0 |
NCT04502082 | Phase Ib/II | ET140203 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ET121) | Recruiting | USA | 0 |
NCT04505839 | Phase I | STP1002 | First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | Recruiting | USA | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Recruiting | USA | CAN | 5 |
NCT04524871 | Phase Ib/II | Atezolizumab + Bevacizumab + Tocilizumab Atezolizumab + Bevacizumab + MTIG7192A Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Recruiting | USA | 6 |
NCT04541173 | Phase II | Atezolizumab + Bevacizumab | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | Recruiting | USA | 0 |
NCT04563338 | Phase II | Atezolizumab Atezolizumab + Bevacizumab | Study of How Atezolizumab and Bevacizumab Affects the Tumors of Liver Cancer or Lung Cancer With Liver Metastases | Not yet recruiting | CAN | 0 |
NCT04605731 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | Not yet recruiting | USA | 0 |
NCT04634357 | Phase Ib/II | ET140203 | ET140203 T-Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2) | Not yet recruiting | USA | 0 |
NCT04658147 | Phase I | Nivolumab + Relatlimab Nivolumab | Feasibility and Efficacy of Perioperative Nivolumab With or Without Neoadjuvant Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) | Not yet recruiting | USA | 0 |
NCT04696055 | Phase II | Pembrolizumab + Regorafenib | Pilot Study of Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors | Recruiting | USA | 6 |
NCT04721132 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | Not yet recruiting | USA | 0 |